Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2016—SeraCare Life Sciences and the U.S. Department of Commerce National Institute of Standards and Technology have signed a three-year cooperative research and development agreement (CRADA) to advance the development of circulating tumor DNA diagnostic assay reference standard materials.
August 2016—GenMark Diagnostics received the CE mark for its ePlex Instrument System and ePlex Respiratory Pathogen (RP) Panel. The panel detects 20 viral and three bacterial targets in nasopharyngeal specimens.
August 2016—Qiagen has entered into a licensing and co-development agreement with Munich-based Therawis Diagnostics to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict the effectiveness of anthracycline treatment in triple-negative and other high-risk breast cancer patients.
August 2016—The Tissue-Tek Cryo3 Flex Cryostat, from Sakura Finetek USA, produces sections from 1 to 99 µm using a temperature-controlled blade holder and a 3-D precision chuck to accurately align the block face to the blade, reducing user’s trimming time and preserving specimens.
July 2016—SciGene introduced its MicroFISH Assay System, a clinically validated method combining microvolume, multiwell slides with SciGene slide processing instruments to perform routine cellular fluorescence in situ hybridization in cytogenetic laboratories.
July 2016—Invitrogen SuperScript IV VILO Master Mix from Thermo Fisher Scientific is a cDNA reaction master mix designed for two-step quantitative PCR (RT-qPCR) applications. The master mix format uses variable input, linear output technology and combines optimized buffer conditions with Invitrogen SuperScript IV reverse transcriptase.
Under terms of an agreement with Illumina, ArcherDx will lead the development of a series of diagnostic tests, using ArcherDx’s Anchored Multiplex PCR chemistry, that will run on the Illumina MiSeqDx instrument.
July 2016—Genomics plc, a company that develops algorithms and software solutions to uncover the relationships between genetic variation and human disease, has entered into a research collaboration with DNAnexus, a cloud-based genome informatics and data management platform.
July 2016—Bio-Rad Laboratories released its Liquichek Maternal Serum II Control, a frozen liquid human serum-based material designed to monitor the precision of laboratory test procedures used during maternal serum second trimester screening.
July 2016—Bioo Scientific has launched the Nextflex BRCA1 and BRCA2 Amplicon Panel for FFPE Illumina-compatible sequencing. The panel detects clinically relevant somatic mutations in DNA isolated from formalin-fixed, paraffin-embedded samples to facilitate variant discovery and confirmation.
